Antibody-Drug Conjugates in Oncology

Описание: 'Antibody-Drug Conjugates in Oncology' by Danna M. Markides, Assistant Professor, Department of Emergency Medicine, Division of Internal Medicine, MD Anderson Cancer Center, University of Texas

BRIEF SUMMARY

Antibody-drug conjugates (ADCs) are novel antineoplastic agents whose use is rapidly expanding, both in terms of the number of approved drugs and the number of patients being treated. This is a rapidly evolving field; of the 12 ADCs approved for cancer treatment in the EU, 8 have received approval in the past five years. While an improved safety profile is a key advantage of this therapeutic class, ADCs are nonetheless associated with serious, and in some cases fatal, adverse reactions.

In this session, we will review the known toxicities and complications of ADCs currently approved in the EU for cancer treatment, with a focus on their emergency presentations and appropriate management strategies.


ABOUT THE SPEAKER

Dr Markides attended medical school at the University of Texas Medical Branch and completed a residency in Emergency Medicine at the University of Rochester. She practised general Emergency Medicine in Houston for over 20 years before joining the faculty at MD Anderson. She is currently an Assistant Professor in the Department of Emergency Medicine and provides clinical care at MD Anderson’s Acute Cancer Care Centre.

She has worked on quality initiatives to improve the number of safe ED discharges and to ensure that care provided overnight is equitable to that available by day.

Her research focuses on complications and adverse events associated with novel cancer therapies, with particular attention to emergency department presentation and management.